跳至主要内容
临床试验/NCT03793088
NCT03793088招募中不适用

xCures/CancerCommons Enhanced Learning Treatment Selection and Analysis With Outcomes Research (XCELSIOR) Study: A Patient-Centric Platform Trial for Precision Oncology

xCures1 个研究点 分布在 1 个国家目标入组 10,000 人开始时间: 2019年2月7日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
10,000
试验地点
1
主要终点
Overall Survival (OS)

研究概览

简要总结

XCELSIOR is a non-interventional data registry. Information about treatments, treatment decisions and rationale, and patient outcomes including safety and effectiveness of anti-cancer therapy and associated supportive care will be collected for analysis.

详细描述

XCELSIOR is patient-centric study for the registration of cancer patients, operations of a virtual tumor board, insight capture in clinical decision making, and collection of longitudinal, observational data in a cancer registry. Patient intake into XCELSIOR will occur through the Cancer Commons Web portal. This includes consent to participate in the data registry, including the collection and review of medical information by a Virtual Tumor Board, generation of patient-specific treatment options with supporting rationale, access to treatment access support services, and inclusion into a registry study that includes safety and efficacy outcomes tracking. Patients will be treated and tracked in their original treatment setting and the data generated will form part of a systematic framework combining expert judgment with artificial intelligence to maximize information gain and improve treatment option set development for individual cancer patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
0 Years 至 —(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Both male and female patients with known or suspected recalcitrant or advanced cancer are eligible to enroll through the Cancer Commons Website
  • Patients with any performance status, comorbidity or disease severity are eligible
  • Patients or their legally-authorized representative must be willing and able to provide written, informed consent (and assent, if applicable)

排除标准

  • Patients must be a resident of or receiving care within the United States or US territories.

结局指标

主要结局

Overall Survival (OS)

时间窗: 5 years

Progression Free Survival (PFS)

时间窗: 5 Years

次要结局

未报告次要终点

研究者

发起方
xCures
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验